Orthohepadnavirus Infections is an indication for drug development with over 250 pipeline drugs currently active. According to GlobalData, preregistered drugs for Orthohepadnavirus Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Orthohepadnavirus Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Orthohepadnavirus Infections overview

Orthohepadnavirus is a genus of viruses, in the family Hepadnaviridae. Humans and other mammals serve as natural hosts. There are 12 species in this genus. Diseases associated with this genus include: hepatitis, hepatocellular carcinoma (chronic infections), and cirrhosis. Orthohepadnavirus virions are spherical, 42–50nm in diameter, and are composed of an approximately 34nm icosahedral nucleocapsid (core) that contains the viral DNA. Hepadnavirus B (hepatitis B virus, HBV) belongs to the genus Orthohepadnavirus of the family Hepadnaviridae and is an important cause of viral hepatitis in humans worldwide. HBV is a double-shelled, enveloped DNA virus belonging to the family Hepadnaviridae (genus Orthohepadnavirus).

For a complete picture of PTSR and LoA scores for drugs in Orthohepadnavirus Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.